Evercore ISI Sticks to Its Buy Rating for Omada Health, Inc. (OMDA)

Evercore ISI analyst Elizabeth Anderson CFA maintained a Buy rating on Omada Health, Inc. yesterday and set a price target of $25.00. The company’s shares closed yesterday at $11.17.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Anderson CFA is an analyst with an average return of -3.1% and a 47.09% success rate. Anderson CFA covers the Healthcare sector, focusing on stocks such as Align Tech, Humana, and Doximity.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Omada Health, Inc. with a $25.43 average price target.

Based on Omada Health, Inc.’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $68.03 million and a GAAP net loss of $3.18 million. In comparison, last year the company earned a revenue of $35.1 million and had a GAAP net loss of $18.97 million

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OMDA in relation to earlier this year. Last month, Sean P. Duffy, the CEO of OMDA sold 271,275.00 shares for a total of $4,244,157.66.